Clinicopathological features and prognostic significance of HER2-low status in breast carcinoma

被引：0
|
作者：
Ilieva-Shipchanova, N. [1 ]
Tashkova, D. [1 ]
Bangieva, E. [1 ]
Miteva, N. [1 ]
机构：
[1] Med Univ Plovdiv, Complex Oncol Ctr Plovdiv, Plovdiv, Bulgaria
来源：
VIRCHOWS ARCHIV | 2024年 / 485卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
E-PS-02-03
引用
收藏
页码：S194 / S194
页数：1
相关论文
共 50 条
  • [1] The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status
    Gamrani, Sanaa
    Akhouayri, Laila
    Boukansa, Sara
    Karkouri, Mehdi
    El Fatemi, Hinde
    BREAST JOURNAL, 2023, 2023
  • [2] The clinicopathological and prognostic significance of HER2-low breast cancer: A comparative analysis between HER2-low and HER2-zero subtypes
    Nishimura, Reiki
    Fujiki, Yoshitaka
    Taira, Tetsuhiko
    Miyaki, Toshiko
    Kanemitsu, Shuichi
    Yotsumoto, Daisuke
    Teraoka, Megumi
    Kawano, Junko
    Gondo, Naomi
    Mitsueda, Reiko
    Baba, Shinichi
    Ohi, Yasuyo
    Rai, Yoshiaki
    Sagara, Yoshiaki
    Sagara, Yasuaki
    CANCER RESEARCH, 2024, 84 (09)
  • [3] The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero Subtypes
    Nishimura, Reiki
    Fujiki, Yoshitaka
    Taira, Tetsuhiko
    Miyaki, Toshiko
    Kanemitsu, Shuichi
    Yotsumoto, Daisuke
    Teraoka, Megumi
    Kawano, Junko
    Gondo, Naomi
    Mitsueda, Reiko
    Baba, Shinichi
    Ohi, Yasuyo
    Rai, Yoshiaki
    Sagara, Yoshiaki
    Sagara, Yasuaki
    CLINICAL BREAST CANCER, 2024, 24 (05) : 431 - 438
  • [4] Clinicopathological Features and Fluorescent in Situ Hybridization Profile of HER2-Low Breast Carcinoma
    Hu, Yan
    Jones, Dan
    Zhao, Weiqiang
    Tozbikian, Gary
    Parwani, Anil
    Li, Zaibo
    LABORATORY INVESTIGATION, 2023, 103 (03) : S145 - S146
  • [5] Clinicopathological features and prognosis of patients with HER2-low breast cancer
    Xin Yang
    Yao Li
    Xu lu
    Xiaotian Ren
    Bin Hua
    BMC Cancer, 23 (1)
  • [6] Clinicopathological features and prognosis of patients with HER2-low breast cancer
    Yang, Xin
    Li, Yao
    Lu, Xu
    Ren, Xiaotian
    Hua, Bin
    BMC CANCER, 2023, 23 (01)
  • [7] Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine
    Kitadai, Rui
    Shimoi, Tatsunori
    Yazaki, Shu
    Okuma, Hitomi Sumiyoshi
    Hoshino, Mai
    Ito, Munehiro
    Saito, Ayumi
    Kita, Shosuke
    Kojima, Yuki
    Nishikawa, Tadaaki
    Sudo, Kazuki
    Noguchi, Emi
    Fujiwara, Yasuhiro
    Yoshida, Masayuki
    Yonemori, Kan
    BREAST CANCER, 2024, 31 (06) : 1037 - 1045
  • [8] HER2-Low Luminal Breast Carcinoma Is Not a Homogenous Clinicopathological and Molecular Entity
    Andre, Celine
    Bertaut, Aurelie
    Ladoire, Sylvain
    Desmoulins, Isabelle
    Jankowski, Clementine
    Beltjens, Francoise
    Charon-Barra, Celine
    Bergeron, Anthony
    Richard, Corentin
    Boidot, Romain
    Arnould, Laurent
    CANCERS, 2024, 16 (11)
  • [9] Assessment of HER2-Low Status in HER2-Mutant Breast Carcinoma
    Yang, Ellen
    Pareja, Fresia
    Rana, Satshil
    Brannon, A.
    Vanderbilt, Chad
    Dikoglu, Esra
    Grabenstetter, Anne
    Wen, Hannah
    Brogi, Edi
    Ross, Dara
    LABORATORY INVESTIGATION, 2024, 104 (03) : S313 - S315
  • [10] HER2-Low Luminal Breast Carcinoma Is Not a Homogenous Clinicopathological and Molecular Entity
    Andre, Celine
    Bertaut, Aurelie
    Ladoire, Sylvain
    Desmoulins, Isabelle
    Jankowski, Clementine
    Barra, Celine Charon
    Beltjens, Francoise
    Bergeron, Anthony
    Richard, Corentin
    Boidot, Romain
    Arnould, Laurent
    LABORATORY INVESTIGATION, 2023, 103 (03) : S89 - S91
12345